Oral Vancomycin Prophylaxis Is Highly Effective in Preventing Clostridium difficile Infection in Allogeneic Hematopoietic Cell Transplant Recipients
- 26 September 2018
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 68 (12) , 2003-2009
Abstract
Clostridiumdifficile infection (CDI) is a leading cause of infectious complications in allogeneic hematopoietic cell transplant recipients (alloHCT). We sought to evaluate whether prophylactic oral vancomycin reduces the incidence of CDI in alloHCT recipients. We conducted a retrospective cohort study to examine the effectiveness of CDI prophylaxis with oral vancomycin compared to no prophylaxis in 145 consecutive adult alloHCT recipients at the University of Pennsylvania between April 2015 and November 2016. Patients received oral vancomycin 125 mg twice daily starting on admission and continued until discharge. The primary outcome of interest was the association between oral vancomycin prophylaxis and CDI diagnosis. Secondary outcomes included graft-versus-host-disease (GVHD) and relapse. There were no cases of CDI in patients that received prophylaxis 0/90 (0%) whereas 11/55 (20%) patients who did not receive prophylaxis developed CDI (PP=0.12], grade 3 – 4 (sHR 0.65; 95% CI, 0.25 – 1.66; P=0.36), or grade 2 – 4 gastrointestinal GVHD (sHR 1.95; 95% CI, 0.93 - 4.07; P=0.08) at day 180 post-transplant. No associations between oral vancomycin and relapse or survival were observed.Keywords
Funding Information
- National Institutes of Health (K01-AI103028)
This publication has 38 references indexed in Scilit:
- Impact of oral vancomycin on gut microbiota, bile acid metabolism, and insulin sensitivityJournal of Hepatology, 2014
- Clostridium difficile: Deleterious Impact on Hematopoietic Stem Cell TransplantationCurrent Hematologic Malignancy Reports, 2014
- Changing Epidemiology of Clostridium difficile–Associated Disease during Stem Cell TransplantationTransplantation and Cellular Therapy, 2013
- Clostridium difficile Infection after Allogeneic Hematopoietic Stem Cell Transplantation: Incidence, Risk Factors, and OutcomeTransplantation and Cellular Therapy, 2012
- Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantationJournal of Experimental Medicine, 2012
- Epidemiology and Outcomes of Clostridium difficile Infections in Hematopoietic Stem Cell Transplant RecipientsClinical Infectious Diseases, 2012
- Clostridium difficile‐associated disease in allogeneic hematopoietic stem‐cell transplant recipients: risk associations, protective associations, and outcomesClinical Transplantation, 2010
- Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global PerspectiveTransplantation and Cellular Therapy, 2009
- National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. Diagnosis and Staging Working Group ReportTransplantation and Cellular Therapy, 2005
- Prevention of infection and graft-versus-host disease by suppression of intestinal microflora in children treated with allogeneic bone marrow transplantationEuropean Journal of Clinical Microbiology & Infectious Diseases, 1990